Valuation: Shield Therapeutics plc

Market Cap 63.66M 84.22M 74.83M 69.84M 120M 8.1B 121M 845M 328M 4.14B 316M 309M 13.28B P/E 2026 *
403x
P/E 2027 * 8.15x
Enterprise Value 82.11M 109M 96.52M 90.09M 155M 10.44B 156M 1.09B 422M 5.34B 408M 399M 17.13B EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.17x
Free-Float
38.1%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 day-1.65%
1 week+14.42%
Current month-1.16%
1 month+2.59%
3 months-1.65%
6 months-30.81%
Current year-39.59%
1 week 5.1
Extreme 5.1
6.1
1 month 4.4
Extreme 4.4
6.1
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/2/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/2/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
-1.65%+14.42%-23.72%-21.19% 85.52M
-0.45%-3.08%+39.90%+113.08% 1,025B
-1.28%-5.84%+37.31%+64.60% 623B
+1.22%-0.56%+11.12%+77.32% 459B
+0.20%-3.27%+60.78%+40.33% 355B
-0.95%-4.05%+21.60%+39.37% 336B
-1.46%-2.89%+11.84%+24.60% 270B
-1.35%-5.43%-4.69%+8.40% 247B
-0.98%-2.58%+35.81%+51.67% 220B
-1.97%-4.35%+30.58%+94.82% 183B
Average -0.90%+0.77%+22.05%+49.30% 371.83B
Weighted average by Cap. -0.62%-2.11%+30.55%+69.02%

Financials

2026 *2027 *
Net sales 53.48M 70.76M 62.87M 58.68M 101M 6.8B 102M 710M 275M 3.48B 266M 260M 11.16B 69.92M 92.5M 82.19M 76.71M 132M 8.89B 133M 928M 360M 4.55B 347M 340M 14.59B
Net income 258K 341K 303K 283K 487K 32.81M 491K 3.43M 1.33M 16.77M 1.28M 1.25M 53.84M 7.74M 10.24M 9.1M 8.5M 14.6M 985M 14.74M 103M 39.84M 503M 38.46M 37.63M 1.62B
Net Debt 18.45M 24.41M 21.69M 20.24M 34.8M 2.35B 35.13M 245M 94.94M 1.2B 91.66M 89.67M 3.85B 18M 23.81M 21.16M 19.75M 33.94M 2.29B 34.26M 239M 92.6M 1.17B 89.4M 87.46M 3.76B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
03/10/26 GBX 5.950 -1.65% 1,281,829
01/10/26 GBX 6.050 +0.50% 2,175,619
30/09/26 GBX 6.020 +7.50% 3,115,032
29/09/26 GBX 5.600 +2.56% 3,260,081
28/09/26 GBX 5.460 +5.00% 1,897,639
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0605GBP
Average target price
0.1667GBP
Spread / Average Target
+175.49%

Annual profits - Rate of surprise